Holger W. Auner, Simona Iacobelli, Giulia Sbianchi, Cora Knol-Bout et al.
Melphalan at a dose of 200 mg/m2 is standard conditioning prior to autologous hematopoietic stem cell transplantation for multiple myeloma, but a dose of 140 mg/m2 is often used in clinical practice in patients perceived to be at risk of excess toxicity. To determine whether melphalan 200 mg/m2 and ...
Sarah Lawless, Simona Iacobelli, Nina Knelange, Patrice Chevallier et al.
Primary plasma cell leukemia (pPCL) is a rare and challenging malignancy. There are limited data regarding optimum transplant approaches. We therefore undertook a retrospective analysis from 1998-2014 of 751 patients with pPCL undergoing one of four transplant strategies; single autologous transplan...
Steve Schey, Sarah Brown, Avie‐Lee Tillotson, Kwee Yong et al.
There is a significant unmet need in effective therapy for relapsed myeloma patients once they become refractory to bortezomib and lenalidomide. While data from the front line setting suggest bendamustine is superior to melphalan, there is no information defining optimal bendamustine dose in multipl...
Curly Morris, Christian Chabannon, Tamás Masszi, Nigel H. Russell et al.
Plerixafor plus granulocyte-colony stimulating factor (G-CSF) enhances the mobilization of hematopoietic stem cells (HSCs) for collection and subsequent autologous hematopoietic stem cell transplantation (HSCT) in patients with multiple myeloma (MM). This international, multicenter, noninterventiona...
Firoozeh Sahebi, S. Iacobelli, Anja van Biezen, Liisa Volin et al.
We performed a retrospective analysis of the European Group for Blood and Marrow Transplantation database comparing the outcomes of multiple myeloma patients who received tandem autologous followed by allogeneic PSCT (auto-allo) with the outcomes of patients who underwent a reduced intensity conditi...
Laurent Garderet, Gordon Cook, Holger W. Auner, Benedetto Bruno et al.
Major improvements have been made in the treatment of myeloma. However, all patients, perhaps with some exceptions, eventually relapse, even after autologous stem cell transplantation (ASCT). In that setting, the combinations of new drugs, namely the IMiDs and the proteasome inhibitors along with st...
Curly Morris, Simona Iacobelli, Gösta Gahrton, Anja van Biezen et al.
We have recently reported on the outcome of autologous transplantation in the rare myelomas (IgD, IgE, IgM, and nonsecretory [NS]) but there is no real information on the outcome of these conditions after allogeneic transplantation. We used the European Group for Blood and Marrow Transplantation mye...
Judith Behrens, Gill Gaskin, Neil Iggo, Jonathan Barratt et al.
Myeloma patients presenting with renal failure continue to have a poor prognosis despite significant advances in anti-myeloma therapy. MERIT was a randomised clinical trial (RCT), set up to evaluate if mechanical reduction of elevated free light chain levels (FLC) would result in clinical benefit. C...
Firoozeh Sahebi, Simona Iacobelli, Anja van Biezen, Liisa Volin et al.
Abstract Background Despite the advances in the treatment of multiple myeloma using new targeted therapies and autologous hematopoietic stem cell transplant (HSCT) the disease remains largely incurable. Recent efforts in using reduced intensity allogeneic HSCT have been hampered by increased allogra...
Gordon Cook, Laurent Garderet, Anja van Biezen, Anja Henseler et al.
Abstract Abstract 4115 Introduction: Polyneuropathy, organomegaly, endocrinopathy, skin changes associated with a paraproteinaemia (POEMS syndrome) is a rare paraneoplastic syndrome secondary to a plasma cell dyscrasia. Effective treatment, including ASCT, of the underlying plasma cell dyscrasia can...
Curly Morris, Marijke Scholten, Liesbeth C. de Wreede, Anja van Biezen et al.
Abstract Abstract 2397 Introduction. DMSO is the universally used cryoprotectant for freezing peripheral blood stem cell for autologous transplantation. DMSO has a significant side effect profile including vasoconstriction, nausea and vomiting and with transplant related mortality now in the region ...
Xavier Leleu, Simona Iacobelli, Alain Barrois, Benjamin Pelle et al.
Abstract Abstract 3340 Background. Immunomodulator drugs (IMiDs) are promising oral agents in Multiple Myeloma (MM); and MM that cannot benefit from novel agents, including IMiDs, only have 9 months survival. On the other hand IMiDs are associated with an increased risk of thromboembolic events (TE)...